Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, announced the launch of iDose TR by Glaukos Corporation using Celanese's VitalDose EVA to provide sustained drug release for the treatment of glaucoma.

The majority of glaucoma and ocular hypertension patients are non-compliant with topical medication use due to complex dosing regiments, side effects, and eye-drop intolerance. Sustained delivery of therapeutics provides an important approach in addressing non-compliance and improving treatment outcomes. With iDose TR and the VitalDose EVA, there is now the opportunity to provide continuous dosing which can improve patient compliance and address adherence issues.

iDose TR was approved by the Food and Drug Administration (FDA) in December 2023 and is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. iDose TR was approved on the basis of two pivotal trials (1,150 subjects randomized across both trials), which demonstrated safety and efficacy.

Glaukos used the VitalDose EVA to create a nanoporous membrane for travoprost delivery in iDose TR. The VitalDose EVA is a platform that can be formulated into a wide range of form factors to suit drug delivery needs for various conditions.

'A clear unmet need exists in ophthalmology for therapies that address non-compliance and reduce the treatment burden for patients,' says Cyonna Holmes, global business strategy leader for Ophthalmology and RNA at Celanese. 'Our team is excited to support Glaukos as they transform the landscape of glaucoma treatment for millions of patients.'

The VitalDose EVA Drug Delivery Platform provides reliable, controlled-release performance and has a long history of use in approved parenteral drug products in the United States and Europe. For more information on Celanese VitalDose technology, visit www.vitaldose.com.

Contact:

Brandon Ayache

Tel: +1 972 443 8509

Email: brandon.ayache@celanese.com

Brian Bianco

Tel: +1 972 443 4400

Email: media@celanese.com

About Celanese

Celanese is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We are committed to sustainability by responsibly managing the materials we create for their entire lifecycle and are growing our portfolio of sustainable products to meet increasing customer and societal demand. We strive to make a positive impact in our communities and foster inclusivity across our teams. Celanese is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.

(C) 2024 Electronic News Publishing, source ENP Newswire